Abstract Details

Title Feasibility and Insights from Automated Depression and Anxiety Screening for People with Epilepsy

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-004

Objective

To describe how systematic screening for depression and anxiety was accomplished in a tertiary epilepsy clinic and describe the insights that the data provided to quality improvement teams.

Background

Mental health comorbidities are highly prevalent among people living with epilepsy (PWE), leading to poor quality of life. Thus, routine screening for anxiety and depression allows for early diagnosis, referral, and treatment of these comorbidities for PWE, improving health outcomes. Mental health screening feasibility concerns have emerged in multiple clinical practices, challenging epilepsy clinics to adopt new practices.

Design/Methods

We conducted a retrospective data analysis from the Electronics Health Record as part of a Quality Improvement initiative in two tertiary epilepsy clinics (Massachusetts General Hospital and Barrow Neurological Institute), comprising January 2019 to October 2022. PWE were offered patient-reported e-questionnaires to create a cohort based on the completion of depression (PHQ-9) and anxiety (GAD-7) screenings. We stratified the records by demographic measures and classified patients based on the severity of depression and anxiety. Moreover, we created a sub-cohort that includes only the records that met Seizure Freedom criteria and calculated the number of observations for Seizure Freedom about the severity of both depression and anxiety.

Results

A total of 813 PWE offering depression and anxiety e-questionnaires were filtered, of which n=500 and n=94 completed PHQ-9 and GAD-7 questionnaires respectively, with a completion rate of 73%. For PHQ-9 completed patients, 54% had no/minimal depression, 20.2% mild depression, 13% moderate depression, and 12.8% severe depression. Most patients achieving seizure freedom were with no/minimal depression. For GAD-7 completed patients, 22.3 % had no/minimal anxiety, 19.2 % mild anxiety, 30.8 % moderate anxiety, and 27.7 % severe anxiety.

Conclusions

Virtual routine screening is feasible in busy tertiary epilepsy clinics as part of care for PWE to identify psychiatric comorbidities, serving as a crucial tool to guide further treatment decisions.

Authors/Disclosures
Lilian Maria Godeiro Coelho, MD PRESENTER	Dr. Godeiro Coelho has nothing to disclose.
Maria Donahue (Massachusetts General Hospital)	Maria Donahue has nothing to disclose.
	No disclosure on file
Poojith Nuthalapati, MD	Mr. Nuthalapati has nothing to disclose.
Jeffrey R. Buchhalter, MD, FAAN (Buchhalter Consulting PLLC)	Dr. Buchhalter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Foundation. Dr. Buchhalter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epilepsy Study Consortium. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biocodex. Dr. Buchhalter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurona.
Brandy Fureman, PhD	Dr. Fureman has received personal compensation for serving as an employee of Epilepsy Foundation. Dr. Fureman has or had stock in EnlitenAI. The institution of Dr. Fureman has received research support from Jazz Pharmaceuticals, Inc. The institution of Dr. Fureman has received research support from NINDS/NIH. The institution of Dr. Fureman has received research support from CDC. Dr. Fureman has a non-compensated relationship as a Owner with Neuroscience Navigators, LLC that is relevant to AAN interests or activities.
Susan T. Herman, MD, FAAN (Barrow Neurological Institute)	The institution of Dr. Herman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bioserenity. Dr. Herman has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for National Association of Epilepsy Centers. Dr. Herman has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Treatment Options in Neurology. Dr. Herman has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Neurophysiology. The institution of Dr. Herman has received research support from Epilepsy Foundation; Epilepsy Learning Healthcare System. The institution of Dr. Herman has received research support from CREMedical. The institution of Dr. Herman has received research support from NIH/NINDS. The institution of Dr. Herman has received research support from Marinus. The institution of Dr. Herman has received research support from Neuroelectrics, Inc. Dr. Herman has received personal compensation in the range of $500-$4,999 for serving as a Medical Director, Neurodiagnostics Program with Laboure College. Dr. Herman has a non-compensated relationship as a Professional Advisory Board member with Epilepsy Foundation that is relevant to AAN interests or activities.
Lidia Maria V. Moura, MD, PhD, MPH, FAAN (Massachusetts General Hospital)	Dr. Moura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Moura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Moura has received research support from Centers for Diseases Control and Prevention (CDC SIP20-007) . The institution of Dr. Moura has received research support from Epilepsy Foundation of America . The institution of Dr. Moura has received research support from NIH - NIA and NINDS. Dr. Moura has received personal compensation in the range of $50,000-$99,999 for serving as a Expert Advisor with Epilepsy Foundation .

��ɫ��

��ɫ��